Analyze the drug structural formula of pemetinib/dalbertam

Pemigatinib (Pemigatinib) is a "selective inhibitor of FGFR1, FGFR2, and FGFR3" and belongs to the small molecule tyrosine kinase inhibitor (TKI) family in terms of chemical properties. Its structural formula contains multiple key segments: aromatic ring structure, heterocyclic structure, amide linking group and hydrophobic side chain. Overall, it exhibits typical characteristics of small molecule oral drugs - stable, easy to penetrate cell membranes, and able to accurately bind to the ATP-binding site of the FGFR kinase domain. It is this ability to "enter the interior of cells and precisely bind to key sites" that gives it the pharmacological properties to inhibit the FGFR signaling pathway.

From a structural perspective, the core structure of pemetinib contains a part called a "pyridine or aromatic-like fragment", which is responsible for occupying a key region of the FGFR kinase pocket in three-dimensional space, thereby blocking ATP binding. The hydrophobic chain at the other end enhances its binding stability, allowing it to show stronger affinity for specific isoforms such as FGFR2. The polar group at the back end of the drug makes it water-soluble, ensuring that it can be absorbed by the body after oral administration. The entire molecular design is a typical "structural optimization result", striving to achieve a balance between selectivity, oral bioavailability and tissue distribution.

Compared with the first-generation broad-spectrum TKI, pemetinib has a more sophisticated structural design. This sophistication is reflected in its precise identification of differences between FGFR isoforms. In the context that FGFR has multiple similar structural domains, the small molecule design team adjusted the side chain length, electron distribution and three-dimensional conformation to make it more likely to bind to FGFR1–3 and reduce the impact on FGFR4. This is also the key reason why many overseas literature calls it a “selective FGFR inhibitor”.

Cholangiocarcinoma patients may worry whether a complex structure means greater toxicity. In fact, the complex structure is not the source of toxicity, but to achieve precise binding and improve safety, thereby avoiding excessive inhibition of irrelevant pathways.

Reference materials:https://go.drugbank.com/drugs/DB15102